An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy : An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy - TRANSITION study

Medienart:

Klinische Studie

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

WHO International Clinical Trials Registry Platform - (2019) vom: 16. Dez. Zur Gesamtaufnahme - year:2019

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Moderate to severe chronic plaque psoriasis MedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Phase: Phase 4
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-04-2019, Last updated: 2022-11-24

ICTRP ID:

EUCTR2019-000817-35-GB
M-14745-41

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG004274016